AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$MAZENeutralLow

Coloma Jason V sold $15K of MAZE

Coloma Jason V (Chief Executive Officer) sold 553 shares of Maze Therapeutics, Inc. (MAZE) at $26.24 on 2026-06-01 under a Rule 10b5-1 trading plan.

Coloma Jason VJune 3, 2026
AI analysis
Relevance
6/10
Novelty
2/10
Actionability
Low
Sentiment · $MAZE
Neutral
Timing
Filed June 3; transaction dated June 1.
Market alignment
Neutral—insider sale under 10b5-1 typically carries less negative read-through.
Why this matters for $MAZE

Insider selling disclosed via Form 4; likely low fundamental signal given stated pre-arranged 10b5-1 plan.

Relevance context

SEC Form 4 shows MAZE CEO Coloma Jason V sold 553 shares in an open-market transaction under a 10b5-1 plan.

Price-impact prediction

Limited near-term impact; any reaction is likely sentiment-driven and small.

Background

This is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.

Why it matters

The market may briefly react to insider selling headlines, but the presence of a pre-arranged 10b5-1 plan generally dampens fundamental interpretation.

Market relevance

Primarily a routine insider transaction; any trading impact is likely small and short-lived.

Market effects

Sector

No clear sector read-through from a single, pre-arranged insider sale.

Regional

None indicated.

Global

None indicated.

Alternative perspectives

Contrarian view

Even 10b5-1 sales can coincide with management views on near-term valuation, so traders may still fade/trim risk if liquidity is thin.

Overlooked factors

The disclosure doesn’t indicate why shares were sold (taxes, diversification, scheduled plan); without additional insider buys/sales context, signal is weak.

Key entities

  • issuer
    Maze Therapeutics, Inc.

    Company whose CEO executed an open-market sale under a Rule 10b5-1 plan.

  • insider
    Coloma Jason V

    CEO and officer/director who sold 553 shares on 2026-06-01.

Read at source← All news

Related articles

APR 8
$MAZEMed

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial

H.C. Wainwright reiterated its Buy rating and $110 price target for Maze Therapeutics (MAZE) after KOL calls validated the HORIZON Phase 2 dataset, confirming the drug's efficacy in different patient cohorts. The data provides a clear path to pivotal trials, suggesting separate non-diabetic and diabetic arms with distinct endpoints. Analysts also noted the potential long-term advantages of MZE829 over competitors and anticipate that upcoming data from Vertex Pharmaceuticals' AMPLIFIED trial could further validate the APOL1 inhibition mechanism.

Streetwise Reports4 min
JAN 1
$MAZELow

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock

Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt recently sold 5,000 shares of company stock in a transaction on December 30th for $200,400, following an earlier sale of 10,000 shares on December 29th for $405,800. After these sales, Bachrodt's direct ownership in the company decreased by 27.83% to 12,965 shares. The stock has seen significant price movement and positive analyst ratings, with an average "Buy" rating and a target price of $43.38 from Wall Street analysts.

MarketBeat2 min